$EMED This may be some helpful information in the case of a “Roll-Up” acquisition and what it might mean for shareholders of EMED. At this point we don't know anything for certain.
AI Overview:
If Electromedical Technologies (EMED) does not withdraw its Form 15-12G by the 90-day deadline, the company's registration will be terminated, it will stop being a public filer, and its stock will be deregistered. This would coincide with a potential "roll-up" by Lionheart Ventures of its partner companies, including EMED, before an initial public offering (IPO) of Lionheart Health.
Here's a breakdown of what that could mean for EMED shareholders.
Consequences of a terminated Form 15-12G
Reduced transparency: A Form 15-12G allows a company to stop its reporting obligations with the Securities and Exchange Commission (SEC), such as filing annual Form 10-Ks and quarterly Form 10-Qs. The termination of its registration would mean less public disclosure about the company's financials and operations.
Reduced liquidity: While a company's stock can still be traded over-the-counter (OTC) after deregistration, it is often much harder to buy and sell due to a significant drop in trading volume.
Voluntary delisting: In August 2024, EMED announced it had filed a Form 15 to voluntarily suspend its SEC reporting obligations. The deregistration process would be completed 90 days after this filing unless withdrawn.
Potential buyout: EMED's Form 15 filing aligns with the previously announced plan from Lionheart Health. In May 2024, Lionheart Health's founder disclosed plans to do a "roll-up acquisition" of key partners, including EMED, before Lionheart Health's IPO, expected in late 2025 or 2026. The Form 15 filing is a necessary step for EMED to be absorbed into a new, private entity.
What the roll-up would mean for EMED shareholders
Acquisition of shares: In a roll-up acquisition, shareholders of the acquired company (EMED) may receive cash for their shares, stock in the new, acquiring company (Lionheart Health), or a combination of both.
Valuation consideration: The value shareholders receive would depend on the terms negotiated by Lionheart Ventures. EMED filed its Form 15 voluntarily as part of a stated financial restructuring, which may influence the terms offered to shareholders.
Loss of standalone investment: Shareholders would lose their direct equity stake in Electromedical Technologies as a standalone public company. Their investment would be converted into a new form, most likely shares of the new, private entity before it goes public.
Timeframe
Form 15 deadline: EMED's registration under Section 12(g) would terminate 90 days after its filing date. EMED filed its Form 15 on July 14, 2025, meaning the termination would take place around October 12, 2025. This aligns with the question's premise.
Lionheart Health IPO: The roll-up of partner companies, including EMED, is expected to occur before Lionheart Health's IPO, which is planned for late 2025 or 2026.
Roll-up completion: The timeframe for the roll-up transaction, including when shareholders would receive their cash or stock, would be determined by the final agreements between Lionheart Ventures and EMED. This would likely happen sometime between the October 2025 deregistration and the planned IPO.
Possible terms for Electromedical Technologies (EMED) shareholders in a Lionheart acquisition could include an all-cash buyout, a stock-for-stock exchange, or a combination of cash and stock. The specific terms would be based on the final acquisition agreement, which has not been publicly detailed. However, an analysis of the situation and Lionheart's previous deals can provide insight into the potential options.
Potential terms for EMED shareholders
1. All-cash buyout:
How it works: Lionheart Ventures offers a set price per share to all EMED shareholders. This is often done via a tender offer, where shareholders can independently decide to sell their shares to the acquirer.
What it means for shareholders:
Certain value: Provides a definite and immediate cash payment for their shares.
Taxable event: The sale of shares for cash will likely be a taxable event.
Relinquish ownership: Shareholders would completely relinquish their ownership in EMED.
2. Stock-for-stock exchange
How it works: Lionheart offers a certain number of shares in its new private entity, Lionheart Health, in exchange for each share of EMED stock. This is a likely scenario given Lionheart's stated plan to "roll-up" EMED and other partners before an IPO.
What it means for shareholders:
Continued equity: Shareholders would maintain an equity stake, but in the new, private company.
Future upside: Their investment value would be tied to the success and future IPO of Lionheart Health, which could occur in 2025 or 2026.
Uncertain valuation: The value of their new shares is not guaranteed and depends on the market at the time of the Lionheart Health IPO.
3. Cash and stock combination
How it works: This is a hybrid deal where shareholders receive a portion of their compensation in cash and the remainder in shares of Lionheart Health.
What it means for shareholders:
Balanced approach: It offers a mix of immediate liquidity from the cash portion and potential future growth from the stock portion.
Complex valuation: The total value of the offer would depend on the negotiated ratio of cash to stock.
Factors influencing the terms
EMED's financial restructuring: In August 2025, EMED announced it filed Form 15 as part of a voluntary financial restructuring. The company has been working to resolve creditor agreements and simplify its capital structure, which could make it an easier target for acquisition. The terms offered to shareholders could be impacted by the outcomes of these restructuring efforts.
Lionheart's roll-up strategy: Lionheart's previous business combinations, often involving SPACs, have seen different shareholder outcomes, including stock-for-stock swaps. This history, combined with the goal of a single, larger entity before an IPO, points towards a stock-based component for EMED shareholders.
Valuation: The specific price per share or stock exchange ratio would be determined by negotiations.
What shareholders should consider
Market conditions: As a delisted stock, EMED shares have already seen significantly reduced transparency and liquidity. Any acquisition offer will be compared to the current OTC market value.
Risk tolerance: Shareholders will need to decide if they prefer a cash payout with a certain value or a stock-based offer that has the potential for future growth but is subject to market risks.
Wait for the definitive agreement: The precise terms will only be known when Lionheart and EMED finalize and announce the acquisition agreement.
AI
Market Data 
Markets 
